–          Multi-center clinical study of 2×3 months, single-blind, comparing Ganfort and Duotrav in reducing intaocular pressure in patients with Pseudoexfoliative Glaucoma or Primary Open Angle Glaucoma treated with Xalacom.

–          Diagnostic accuracy of the Heidelberg Retinal Tomograph 3

–          Multicenter study on age-related biomechanical changes of the cornea

–          THE UK GLAUCOMA TREATMENT STUDY

–          Study of the therapeutic equivalence of latanoprost pk and xalatan. Randomized double-blind clinical study in patients with glaucoma or endo-ocular hypertension

–          Reproducibility and accuracy of the cirrus-OCT

–          Comparison between the Moorfields Multi Location Motion Displacement test (MDT) and conventional perimetry in healthy eyes and sheared glaucoma

–          Study of the epidemiology of glaucomatous disease in the urban population of the city of Rome

–          European retrospective study on the rate of progression of open-angle glaucoma

–          Single-blind, multicenter, three-month pilot study to evaluate the efficacy and safety of the fixed combination bimatoprost / timolol vs latanoprost in patients with open-angle glaucoma at high risk of glaucomatous disease progression never treated before

–          Learning effect of sita-swap perimetry (swedish interactive algorithm short-wavelength) in patients with ocular hypertension

–          Change in the morphological and functional patterns of the ocular surface in patient treated with latanoprost after the use of TSP 0,5% preservative free eyedrops. Randomized, prospective, single masked, multicenter study

–          Reproducibility and accuracy of the RTVue OCT

–          SITA SWAP (Swedish interactive algorithm short-wavelength) perimetry in patients with glaucoma: Evaluation of patients with altered retinal nerve fiber layer with standard SITA and SITA SWAP perimeters

–          Comparison between the incidence and severity of conjunctival hyperemia associated with the topical use of bimatoprost 0.01% and latanoprost 0.005% in glaucomatous or ocular hypertensive patients

–          Comparison between the effects of Bimatoprost 0.01% and Timolol 0.5% on circadian intraocular pressure

–          Evaluation of the genetic characteristics of pigment dispersion syndrome and pigmentary glaucoma and in other forms of glaucoma

–          Phase III, randomized, double-blind, 6-month clinical study with the aim of comparing the efficacy and safety of a preservative-free fixed-dose combination of tafluprost eye drops 0.0015% and timolol eye drops 0 , 5% with tafluprost eye drops 0.0015% and timolol eye drops 0.5% given as monotherapy in patients with open-angle glaucoma or ocular hypertension

–          A 2-year, multicenter, double-masked, randomized, parallel study of the safety of LUMIGAN® 0.1 mg / mL compared with LUMIGAN® 0.3 mg / mL in patients with glaucoma or ocular hypertension

–          Multi-Center Study Comparing Efficacy and Tolerability of TRAVATAN Solution without BAK, containing Polyquad Preservative (0,004% travoprost) in Patients Previously on latanoprost 0,005% or bimatoprost 0,01% ophthalmic solution Monotherapy

–          Evaluation of the therapeutic equivalence of Travoprost Pr and Travatan®. Randomized double-blind clinical study in patients with glaucoma or ocular hypertension.

–          Prot. N ° 006-02-Prospective longitudinal study for the evaluation of the development of diseases on the ocular surface. Comparison between Treatment-Naive patients (not having received specific treatments) with ocular hypertension or glaucoma compared to patients without elevated ocular pressure. (SAHARA)

–          Influence of pupillary dilation in measurements of the retinal nerve fiber layer (RNFL), optic nerve head (ONH) and ganglion cell layer (GCC) with Optical Coherence Tomography (OCT) Spectral Domain (RTVue-100)

–          Learning effect of the Heidelberg Edge Perimeter (HEP) in patients with ocular hypertension.

–          Lumigan 0.1 ® in daily outpatient activity: retrospective study

–          Evaluate the effectiveness of Miotrab administered three times a day in reducing intraocular pressure

–          Efficacy of an ophthalmic solution based on cyanocobalamin, taurine and hyaluronic acid in patients receiving ocular hypotonizing drugs

–          Comparison of the effect of bimatoprost-timolol fixed combination in reducing intraocular pressure versus fixed combinations of carbonic anhydrase inhibitors-timolol in patients with glaucoma or ocular hypertension not controlled by monotherapy: retrospective study

 

–          Intraocular pressure and tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or preservative free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in patients with Ocular hypertension or glaucoma: A Randomized, single masked, 3 month cross- over, Investigator led, European multicentre Trial (SPORT)

–          Side effects of preservatives: clinical, cytological and instrumental evaluation of the ocular surface

–          Evaluation of BDNF and NGF levels in plasma and tears of patients with glaucoma, NTs and glaucoma.

–          Proteomic study of the sclero-corneal trabeculae in glaucoma

–          A phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from Ganfort® eye drops (bimatoprost 0.03% / timolol 0.5%) to Taptiqom® eye drops (tafluprost 0.0015% / timolol 0.5 %).

–          Clinical performance of Compass in the diagnosis of glaucoma: a comparision with HFA (CMP_002)

–          To evaluate the efficacy, safety and tolerability of Bimatoprost 0.01% (BIMMD) and Tafluprost single-dose 15 µg / ml (TUDPF) (SAFLUTAN) in patients with glaucoma or ocular hypertension suitable for prostaglandin therapy: European multicenter study, randomized, cross-over, single blind man, with a masked investigator, lasting six months. (SPORT II)

–          Safety and efficacy with Twice Daily Brinzolamide 1% / Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004% / Timolol 0.5% (DUOTRAV)

–          XEN TREATMENT REGISTER (XEN-GTR)

–          Efficacy of an ophthalmic solution based on aturine and hyaluronic acid in glaucomatous and ocular hypertensive patients in chronic therapy with ocular hypotonizing drugs (OFTAL PLUS)

–          Combination of tafluprost 0.0015% / timolol 0.5% without preservative, fixed dose, in patients with open angle glaucoma or ocular hypertension: clinical efficacy, tolerability and safety in a real life scenario. (0240-0024) LOYADA

–          A prospective, double-masked, randomized, multicenter, active- controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORT® (bimatoprost 0.03% / timolol 0.5%) Ophthalmic Solution in subjects with elevated intraocular pressure (MERCURY 3)

–          Evaluation of the vitreous concentration of Citicoline after topical ocular administration: human ocular pharmacokinetic study OMK12017

–          Study of ocular dominance in patients with glaucoma

–          Evaluation of the effect on the visual function of citicoline in ocular liposomal solution in addition to topical hypotonic therapy in patients with glaucoma. OMK1_LF pre-market clinical investigation

–          Measurement of test retest variability in glaucomatous patients using the compass fundus perimeter CMP-003

–          Evaluation of the efficacy and safety of T4032 (bimatoprost 0.1% without preservatives) compared to Lumigan 0.01% in patients with ocular hypertension or glaucoma-LT4032-301

–          Using crowd-sourced assessment by glaucoma specialists to establish a glaucoma definition for clinical research – CSGS

–          Phase III, multinational, multicenter, investigator masked, randomized, active-controlled study to compare the efficacy and safety of DE-130A versus Xalatan® in patients with open-angle glaucoma or ocular hypertension during 3 months, followed by a 12-month follow-up with open-label DE-130A treatment. CATIOPROST – 0130A01SA

–          24-hour efficacy and tolerability of the fixed combination tafluprost-Timolol without preservatives in glaucoma or ocular hypertensive patients already under treatment with latanoprost preserved with BAK. Prospective study in open for 3 months. HERO

–          Evaluation of spatial summation in the central 10 degrees of the visual field: development of a neural model for structure-function analysis

–          Basic human research study of novel glaucoma endpoints and identification of optimal patient populations forneuroprotection trials CBASICHR0031

–          – A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension TRITON 1698-301-007